VectivBio sold for approximately 1 billion dollars
The takeover of VectivBio is now being finalized: the Boston-based firm Ironwood Pharmaceuticals, which specializes in gastrointestinal medicine, has agreed to acquire the Basel-based biotech firm, which was founded in 2019. The purchase price is estimated to come to an overall value of around 1 billion US dollars.
Ironwood Pharmaceuticals is acquiring the Basel-based biotech firm VectivBio for a price of 17.00 US dollars per share. The all-cash transaction amounts to an estimated total value of around 1 billion US dollars (net of VectivBio cash and debt), further details of which can be found in a press release. The takeover price corresponds to a premium of 80 percent on the average share price over the past 90 trading days
VectivBio is a clinical-stage biotechnology company focused on the discovery and development of therapies to treat serious rare diseases, including short bowel syndrome with intestinal failure (SBS-IF) and acute graft versus host disease. Ironwood, a pharmaceutical firm that focuses on gastrointestinal medicine, is of the conviction that its active ingredient Apraglutide to treat short bowel syndrome, which is currently undergoing a Phase 3 study, is capable alone of generating net sales of 1 billion US dollars overall.
Second major takeover in short time
“Ironwood’s capabilities and established track record in GI make it the ideal company to bring apraglutide, if approved, to patients suffering from SBS-IF and other serious GI conditions. We believe this transaction represents the best outcome for our patients and shareholders”, explains Dr. Luca Santarelli, CEO of VectivBio, in the press release.
This is the already the second major takeover deal for a biotech company from the Basel Area since December 2020. At this time, the German firm Boehringer Ingelheim reinforced its cancer pipeline portfolio with the acquisition of NBE-Therapeutics, a life sciences firm founded in 2012 and headquartered in the Tech Park Basel. The purchase price amounted to 1.18 billion euros.
Share this article
You may also be interested in
Artificial Intelligence – the Holy Grail to Healthcare Innovation?
Last winter, Julia got a cough and a headache. For the third time she went to her physician, who sent...Read More
BaselArea.swiss Presents the DayOne Acceleration Program Supported by Fondation Botnar
Seeking brilliant project ideas that, combined with digital technologies, healthcare expertise and entrepreneurial spirit, will help solve the health challenges...Read More
Investing in strengths – Swiss leadership in life sciences
How can Switzerland and the Basel region maintain their international leadership role in life sciences? As part of the Biotech...Read More
BaseLaunch can take full advantage of the potential of Basel’s life sciences ecosystem
The new accelerator for healthcare ventures, BaseLaunch, wants to link the best start-ups to the Basel region – and in...Read More
Basel impresses with quality of living
Basel is among the top ten cities with the highest quality of living in the world, according to the latest...Read More
“Muttenz is home to the world’s largest plant for the production of 5-HMF from biomass”
Thomas Fischer is Chief Operating Officer with the biotechnology company AVA Biochem in Muttenz.Read More